New FDA Approval in Advanced Breast Cancer: Imlunestrant Plus Abemaciclib for Patients With ESR1 Mutations
The FDA has approved imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy. In the ESR1-mutated subgroup of the EMBER-3 trial, the combination raised median progression-free survival from 5.5 months with imlunestrant alone to 11.1 months.
18 September 2026 — The U.S. Food and Drug Administration (FDA) has approved the combination of imlunestrant (Inluriyo) and abemaciclib (Verzenio) for adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy.
One of the most important innovations in the approval of these drugs, manufactured by Eli Lilly and Company, is that a liquid biopsy test analysing cell-free DNA (ctDNA) from blood (Guardant360 CDx) has received FDA approval as the official companion diagnostic device for this treatment. This development is fully in line with our oncology practice, in which cancer genetics is detected through liquid biopsies and translated directly into a treatment decision (specific ESR1 mutations in the ligand-binding domain).
The EMBER-3 Trial: Rational Combinations Outperform Monotherapy
The approval is based on data from the randomized, open-label EMBER-3 (NCT04975308) clinical trial, which enrolled 874 patients with advanced breast cancer previously treated with aromatase inhibitors (alone or together with a CDK4/6 inhibitor). Patients eligible for a PARP inhibitor were excluded, and participants were assigned to three arms: imlunestrant alone, the investigator's choice of endocrine therapy (fulvestrant or exemestane), and imlunestrant plus abemaciclib.
The results confirm what we frequently emphasise in our Molecular Tumor Boards (MTB): rational drug combinations are superior to single agents in overcoming cellular resistance.
- Progression-free survival (PFS): In the subgroup of 159 patients with ESR1 mutations detected by liquid biopsy, median progression-free survival was 11.1 months with imlunestrant plus abemaciclib, compared with only 5.5 months in the imlunestrant monotherapy group (HR: 0.53).
- Objective response rate (ORR): 15% in the monotherapy arm, rising to 35% in the combination arm.
- Overall survival (OS): Reported as immature, with 35% of events having occurred at the time of the analysis.
The fact that the progression-free survival benefit was seen only in the group with a detected ESR1 mutation confirms how indispensable genomic mapping is for giving the right drug to the right patient.
Clinical Use and Proactive Side Effect Management
The recommended regimen is given as follows until disease progression or unacceptable toxicity:
| Drug | Dose and Administration |
|---|---|
| Imlunestrant | 400 mg once daily (on an empty stomach, at least two hours before or one hour after a meal) |
| Abemaciclib | 150 mg twice daily (with or without food) |
| Duration of treatment | Until disease progression or unacceptable toxicity |
According to the FDA label, the potential side effects reported are:
- Imlunestrant: Embryo-fetal toxicity.
- Abemaciclib: Diarrhea, neutropenia, interstitial lung disease (ILD)/pneumonitis, hepatotoxicity, venous thromboembolism (VTE) and embryo-fetal toxicity.
This pharmacological risk profile confirms once again how vital the pharmacogenomic assessments, proactive organ monitoring and, when needed, rapid dose optimisation that are standard in our clinic are for protecting patients' quality of life.
💬 Important Information for Our Patients
Although the targeted smart drug combination described in this article has been approved by the U.S. Food and Drug Administration (FDA) and included in international guidelines, the official licensing and Social Security Institution (SGK) reimbursement status of these drugs in Turkey may vary. Our clinic plans individualised treatment by sharing openly with our patients the legal conditions of access and the clinical availability in our country of innovative treatments of this kind identified through molecular analysis.
Conclusion
In patients with ESR1-mutated disease that has progressed after endocrine therapy, imlunestrant plus abemaciclib doubled median progression-free survival compared with imlunestrant alone. Because the benefit was seen only in patients with a detected ESR1 mutation, and because this mutation can be identified from blood by liquid biopsy, testing for ESR1 status before choosing treatment becomes decisive. Maturing overall survival data will clarify the long-term place of the combination.
References
- U.S. Food and Drug Administration (FDA). (18 September 2026). FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.